The community speaks

Every year, our program includes keynote speeches by some of the top thinkers and trend-makers in pharma, biotech, medtech, digital health, investment & funding, regulatory.

NLS Days features company presentations organised into tracks that interest specific audiences and fields, for example: pharma and biotechnology in R&D, therapeutics or diagnostics, academic and startup innovators, services providers.

Super Sessions address hot topics in science, business development and market strategies.

In between all of these delightful speaking events, we make sure everyone is refreshed by a classic Swedish ‘fika’ – all that your heart desires, plus lots of coffee.

Dr. Cecilia Ahlin

Medical Head Oncology, Novartis Sweden

11 Sep 15:45 Plenary Room A Seminar 2 – Advanced Therapy Medicinal Products

Mr. Peter Albiez

Country Manager, Pfizer Germany

11 Sep 09:00 Plenary Room A Official Opening Plenary

Dr. Annette Bak

Senior Director – Head of Advanced Drug Delivery, AstraZeneca

12 Sep 14:00 Conference Room B Seminar 5 – Facing the Perfect Storm

Mr. Sverre Bengtsson

Co-Founder, Owner and Senior VP Strategic Relations, PCG Solutions / Viedoc

11 Sep 15:45 Conference Room B Seminar 1 – Drug Discovery & Development

Dr. Sonja Benhamida

Senior Vice President Healthcare, DNB

11 Sep 10:45 Plenary Room A Super Session 1 – Financing

Dr. Magnus R. Björsne

CEO, AZ BioVentureHub

12 Sep 14:00 Conference Room B Seminar 5 – Facing the Perfect Storm

Mr. Daniel Bolanowski

Senior Analyst, Arctic Fund Management

11 Sep 15:45 Plenary Room A Seminar 2 – Advanced Therapy Medicinal Products

Prof. Carl Borrebaeck

Professor, Lund University

12 Sep 10:45 Plenary Room A Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

Dr. George Coukos

Director Department of Oncology, University of Lausanne

12 Sep 10:45 Plenary Room A Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

Mr. Nicolas Creff

Senior Manager, Research Partnerships and Science Policy and Regulatory Affairs, EFPIA

11 Sep 17:15 Conference Room B Seminar 3 – Funding opportunities for SMEs

Dr. Michel de Baar

Executive Director, BD&L - Infectious Diseases, Vaccines, Cardiometabolic, Immunology & Inflammation, MSD

12 Sep 08:45 Plenary Room A Super Session 3 – Metabolic Diseases

Dr. Carlos De Sousa

CEO, Immunicum

11 Sep 15:45 Plenary Room A Seminar 2 – Advanced Therapy Medicinal Products

Dr. Ann-Charlotte Dorange

Health & Value Lead (Health Economics/HTA), Pfizer

11 Sep 17:15 Plenary Room A Seminar 4 – The Nordic Life Science Innovation Landscape

Mr. Olivier Duchamp

Managing Director, NLSDays - VP International BD & Promotion, SwedenBIO

11 Sep 09:00 Plenary Room A Official Opening Plenary

Ms. Caroline Ekstrand

Program Manager, Vinnova

11 Sep 17:15 Conference Room B Seminar 3 – Funding opportunities for SMEs

Dr. Jonas Fransson

Director, SOBI (Swedish Orphan Biovitrum)

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Dr. Per-Ola Freskgård

Vice Director & Distinguished Scientist Neuroscience, pRED Roche Innovation Center

11 Sep 14:00 Plenary Room A Super Session 2 – Neurosciences

Dr. Peter Gaskin

Senior Director, Scientific Advisory Services, Charles River Laboratories

11 Sep 15:45 Conference Room B Seminar 1 – Drug Discovery & Development

Mr. Thomas Gidlund

Investment Manager, Sciety

11 Sep 10:45 Plenary Room A Super Session 1 – Financing

Mr. Leo Groenewegen

Business Developer, NextCell Pharma

11 Sep 15:45 Plenary Room A Seminar 2 – Advanced Therapy Medicinal Products

Dr. Thomas Grotkjaer

Principal, Novo Holdings

11 Sep 10:45 Plenary Room A Super Session 1 – Financing

Dr. Lars Gustafsson

Expert, Healthcare Digitalization - CGI/KI

12 Sep 08:45 Plenary Room A Super Session 3 – Metabolic Diseases

Dr. Rob Harris

Director Science and Technology, Catalent Pharma Solutions

12 Sep 08:45 Plenary Room A Super Session 3 – Metabolic Diseases

Mr. Petter Hartman

CEO, Medicon Valley Alliance

Ms. Ingrid Heath

Partner, Adlersson & Heath

11 Sep 14:00 Plenary Room A Super Session 2 – Neurosciences

Ms. Kaisa Helminen

CEO, Aiforia Technologies

12 Sep 10:45 Plenary Room A Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

Mr. Hans Erik Henriksen

CEO, HealthCare Denmark

11 Sep 09:00 Plenary Room A Official Opening Plenary

Dr. Anders Holmén

VP and Head of Pharmaceutical Sciences, BioPharmaceuticals R&D, AstraZeneca

Mr. Antonio Iervolino

Associate Principal, IQVIA

11 Sep 15:45 Conference Room B Seminar 1 – Drug Discovery & Development

Ms. Louise Jonshammar

Attorney At Law, AWA

11 Sep 17:15 Plenary Room A Seminar 4 – The Nordic Life Science Innovation Landscape

Mr. Adam Kostyal

Senior Vice President, Nasdaq OMX

11 Sep 10:45 Plenary Room A Super Session 1 – Financing

Mr. Marko Kuisma

Chief Commercial Officer, Kaiku Health

12 Sep 10:45 Plenary Room A Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

Mr. Ari-Pekka Laitsaari

Growth Capital and Innovation Finance, European Investment Bank

11 Sep 10:45 Plenary Room A Super Session 1 – Financing

Dr. Magnus Larsson

Vice President, Head of Unit Surface - Process and Formulation, RISE

11 Sep 17:15 Plenary Room A Seminar 4 – The Nordic Life Science Innovation Landscape

Dr. Roman Lassnig

Development Engineer, Printed Electronics, Biocom Lab/RISE

11 Sep 14:00 Plenary Room A Super Session 2 – Neurosciences

Ms. Ann Linde

Swedish Minister for Foreign Trade, with responsibility for Nordic affairs

11 Sep 09:00 Plenary Room A Official Opening Plenary

Mr. Patrik Ling

Senior Analyst HealthCare, DNB Markets

11 Sep 10:45 Plenary Room A Super Session 1 – Financing

Mr. Shutian Liu

Managing Partner and Founding Partner, Button Capital

11 Sep 10:45 Plenary Room A Super Session 1 – Financing

Dr. Lotta Ljungqvist

President & CEO GE Nordics & CEO Testa Center at GE Healthcare

11 Sep 09:00 Plenary Room A Official Opening Plenary

Assoc. Prof. Tomas Lundqvist

Coordinator for Large Scale Research Infrastructures, RISE

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Mr. Thomas Magnusson

Chairman of the Board, The Diabetes Organisation of Sweden

12 Sep 08:45 Plenary Room A Super Session 3 – Metabolic Diseases

Dr. Selma Maric

Coordinator Industrial Relation, Life Sciences, MAX IV

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Mr. Fredrik Melander

Head of R&D Relations, Science Village Scandinavia

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Dr. Eric Meldrum

CSO, ENYO Pharma

11 Sep 15:45 Conference Room B Seminar 1 – Drug Discovery & Development

Dr. John Montana

Corporate VP, Integrated Drug Discovery & Strategic Projects, Charles River Laboratories

11 Sep 15:45 Conference Room B Seminar 1 – Drug Discovery & Development

Dr. Elisabet Nielsen

Program Manager, Vinnova

11 Sep 17:15 Conference Room B Seminar 3 – Funding opportunities for SMEs

Dr. Niclas Nilsson

Head of Open Innovation in Research, LEO Pharma

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

11 Sep 17:15 Plenary Room A Seminar 4 – The Nordic Life Science Innovation Landscape

Dr. Per Norlén

CEO, Alligator Bioscience

Prof. Lene Oddershede

Head of grants for research, Novo Nordisk Foundation

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Dr. Björn Odlander

Managing Partner, HealthCap

11 Sep 15:45 Plenary Room A Seminar 2 – Advanced Therapy Medicinal Products

Prof. Malin Parmar

Associate Professor, Lund University

11 Sep 15:45 Plenary Room A Seminar 2 – Advanced Therapy Medicinal Products

Assoc. Prof. Kajsa Paulsson

Session's Chairman, Associate Professor, Lund University

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Prof. Kristian Pietras

Professor of Molecular Medicine, Lund University

12 Sep 10:45 Plenary Room A Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

Ms. Magali Poinot

Advisor to Executive Director, IMI Executive Office

11 Sep 17:15 Conference Room B Seminar 3 – Funding opportunities for SMEs

Prof. Erik Renström

Professor, Lund University

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Dr. Michael L. Salgaller

Supervisor, Invention Development and Marketing Unit (IDMU), National Institutes of Health

11 Sep 17:15 Plenary Room A Seminar 4 – The Nordic Life Science Innovation Landscape

Dr. Gunnar Sandberg

Chair of IMI State Representative Group and Program Manager, Vinnova

11 Sep 17:15 Conference Room B Seminar 3 – Funding opportunities for SMEs

Dr. Anna Sandström

Science Policy and Relations Director Europe, AstraZeneca

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Dr. Uwe Sassenberg

Head EU-Projects, Innovation and Technology Transfer, DESY

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Dr. Ulrica Sehlstedt

Partner, Arthur D. Little

12 Sep 14:00 Conference Room B Seminar 5 – Facing the Perfect Storm

Dr. Jørn Skibsted Jakobsen

Vice President, Global Clinical Research and Development, Ferring Pharmaceuticals

12 Sep 10:45 Plenary Room A Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

Dr. Patrick Sobocki

Investment Manager, Industrifonden

11 Sep 14:00 Plenary Room A Super Session 2 – Neurosciences

11 Sep 10:45 Plenary Room A Super Session 1 – Financing

Dr. Anna Stenstam

CEO, CR Competence

12 Sep 14:00 Conference Room C Seminar 6 – MAX IV – ESS – HALOS

Mr. Terje Straume

Global Head HealthCare, DNB Bank

11 Sep 09:00 Plenary Room A Official Opening Plenary

Ms. Helena Strigård

Deputy Director General, SwedenBIO

11 Sep 09:00 Plenary Room A Official Opening Plenary

Dr. Jina Elise Swartz

Global Clinical Development, MSD

11 Sep 14:00 Plenary Room A Super Session 2 – Neurosciences

Dr. Mark Swindells

Chief Operating Officer, Exscientia

12 Sep 10:45 Plenary Room A Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

Dr. Gaspar Taroncher-Oldenburg

Editor-at-Large, Nature Publishing Group

12 Sep 10:45 Plenary Room A Super Session 4 – Cancer Precision Medicine: state-of-the-art and future directions

12 Sep 08:45 Plenary Room A Super Session 3 – Metabolic Diseases

Dr. Steffen Thirstrup

Director, NDA Regulatory Advisory Board

11 Sep 14:00 Plenary Room A Super Session 2 – Neurosciences

Dr. Damon Tojjar

Managing Director, Easy Diabetes

12 Sep 08:45 Plenary Room A Super Session 3 – Metabolic Diseases

Dr. Thomas Unger

Associate Director, Arthur D. Little

12 Sep 14:00 Conference Room B Seminar 5 – Facing the Perfect Storm

Dr. Christoph Varenhorst

Medical Director, Pfizer

11 Sep 15:45 Plenary Room A Seminar 2 – Advanced Therapy Medicinal Products

Dr. Karin von Wachenfeldt

CEO, Truly Labs

11 Sep 17:15 Conference Room B Seminar 3 – Funding opportunities for SMEs

Mr. Sijme Zeilemaker

Sr. Director Business Development, Immunicum

Dr. Christina Östberg Lloyd

Clinical Medical Regulatory Director, Novo Nordisk & Chairman, Swelife

11 Sep 15:45 Plenary Room A Seminar 2 – Advanced Therapy Medicinal Products